Cahill Represents Initial Purchasers in Notes Offering and Lead Arrangers of Credit Facilities for Catalent Pharma Solutions, Inc.
Cahill represented the initial purchasers in connection with a Rule 144A offering of $550,000,000 aggregate principal amount of 3.125% senior notes due 2029 by Catalent Pharma Solutions, Inc. (the “Company”). Cahill also represented lead arrangers in connection with an incremental $66,625,000 term B credit facility and $175,000,000 revolving credit facility for the Company. Proceeds from the notes offering and credit facilities were used to refinance existing indebtedness and for general corporate purposes. Catalent Pharma Solutions, Inc. is a multinational corporation involved in technology and development for drugs, biologics and consumer health products.